Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

ABSTRACT: Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

PROVIDER: PRJNA966137 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [patient glioblastoma tumors]

Project description:Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [patient glioblastoma tumors]

| PRJNA955813 | ENA

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [RNA-Seq]

Project description:Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [RNA-Seq]

| PRJNA1279849 | ENA

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [patient glioblastoma tumors]

Project description:Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. One of the most significant issues hindering GBM therapeutic development is intratumor heterogeneity. GBM tumors consist of multiple neoplastic cell types with distinct transcriptional profiles. Identifying compounds that target these different cell types requires a platform that predicts differential sensitivity and resistance of cells within GBM tumors. To address this, we developed a novel framework to generate tumor cell-type-specific disease signatures and their predicted drug sensitivity. We performed single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors and identified compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct single-cell transcriptional states within GBM tumors. We then validated in silico predictions with in vivo findings in mice as the aurora kinase inhibitor alisertib induced a shift from NPC-like to MES-like transcriptional states upon treatment. To allow other investigators to predict selective tumor cell type drug sensitivity in silico we developed a platform termed ISOSCELES (Inferred cell Sensitivity Operating on the integration of Single-Cell Expression and L1000 Expression Signatures). Our studies suggest that ISOSCELES is a novel platform to identify cell populations that are sensitive and resistant to targeted therapies in GBM, which can inform treatment decisions in future clinical trials.

2025-01-31 | GSE229779 | GEO

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [RNA-Seq]

2025-06-23 | GSE300210 | GEO

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [PDX GBM22 orthotopic xenografts]

Project description:Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [PDX GBM22 orthotopic xenografts]

| PRJNA966142 | ENA

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations [PDX GBM22 orthotopic xenografts]

2025-01-31 | GSE231489 | GEO

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-01-31 | GSE231490 | GEO

Glioblastoma cell supermeres

Project description:Glioblastoma cell supermeres

| PRJNA1136530 | ENA

Human BRAF-V600E melanoma cell lines drug sensitive vs drug resistant

Project description:aCGH of human melanoma cell lines comparing parental (drug sensitve) vs isogenic drug resistant-derived subline Two condition experiment: two BRAF-V600E mutant cell lines (drug sensitive - parental baseline) vs two derived sublines after chronic exposure to the MEK inhibitor trametinib (drug resistant) are compared

2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress

LncRNA expression data from BRCA drug-sensitive and drug-resistant cell lines

Project description:LncRNA expression data from BRCA drug-sensitive and drug-resistant cell lines

| PRJNA649906 | ENA